Oral antibiotic eye infection tablets can be an effective medication for a treatment-resistant sex bug

An oral antibiotic tablet used to treat common eye infections could prove an effective drug for a sexually transmitted bug that has become resistant to commonly recommended treatments, doctors suggest in the journal. sexually transmitted infections.

They successfully treated a young man Mycoplasma genitalium (non-gonococcal) chloramphenicol urethritis.

Figures from the UK Health Protection Agency suggest that antimicrobial resistance is increasing in the first- and second-line drugs used to treat this infection, while there is currently no strong evidence for the third-line option, the authors say.

They describe the case of a young man with symptoms of recurrent non-gonococcal urethritis, caused by a common sexually transmitted infection. Mycoplasma genitalium which have become increasingly difficult to treat with currently prescribed antibiotics.

Fifteen days after having unprotected sex with a friend, the young man initially presented to the clinic with 2-day-old symptoms.

She was initially treated with a one-week course of doxycycline pending test results to identify the exact bacterial cause of her infection.

The results showed that he was infected M Genitalia And then she was given another antibiotic, azithromycin. Once laboratory analysis revealed that it was a treatment-resistant strain, she was then given a third antibiotic, moxifloxacin.

But even after 5 days of completing all the courses of antibiotics, he started showing symptoms. After considering other options that were dismissed due to cost, availability, or licensing issues, the authors decided to try chloramphenicol: 1 g tablet taken four times a day for 14 days.

Their decision was prompted by test tube evidence that chloramphenicol was discontinued M Genitalia On its track and ready availability of medicine.

After 14 days of treatment, the young man’s symptoms cleared up and laboratory tests confirmed that he no longer had urethritis.

This is just one case, and conclusions should be taken in that context. But point out the authors: “When considering what to choose after first- and second-line treatment failure, there is a lack of readily available novel agents in the UK, and a lack of data to inform recommendations.”

Chloramphenicol is generally well tolerated, with serious side effects rare (1 in 30,000), they highlight. And in the absence of viable effective alternatives, it merits further research, they suggest.

“Options for Third-Line Treatment in Treatment-Resistant M Genitalia urgently needed. Chloramphenicol may have application in this scenario, and is considered as a potential drug for investigation,” they conclude.